Middle East & Africa Colorectal Cancer Market Forecast to 2028 – COVID

Middle East & Africa Colorectal Cancer Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Modality (Diagnosis Type, Therapy Type, and Imaging Type) and End User (Hospitals and Diagnostic & Research Laboratories)

Report Code : BMIRE00026182 | Region : LAMEA | Industry : Pharmaceuticals | Published Date : 23/Sep/2022

The colorectal cancer market in the Middle East & Africa is expected to grow from US$ 885.81 million in 2022 to US$ 1,076.92 million by 2028; it is estimated to grow at a CAGR of 2.5% from 2022 to 2028.

Numerous benefits offered by generic drugs is among the major factor driving the growth of the Middle East & Africa colorectal cancer market. Generic drugs are alternatives to branded drugs. The pharmacological effects of generic drugs are similar to their branded counterparts. Generic drugs are cost-effective as the manufacturers do not invest in developing and marketing a new drug. After the expiry of a drug patent, other manufacturers apply for FDA approval of a generic intended for its manufacturing and selling. Thus, generic drugs are cheaper than their branded counterparts. Generic drugs have the same dosage, effects and side effects, route of administration, risks, safety, and strength as the original branded drugs.

Generic drugs are important in oncology because some anticancer drugs are only offered as generics. Patients are likely to abandon branded prescriptions associated with their higher prices. Generic drugs for cancer treatment are profitable for manufacturers and patients due to their affordability and efficacy, especially in developing countries in the Middle East & Africa, where the paying capacity of consumers is relatively low. Thus, the preference for generic drugs among consumers and the high adoption of generic drugs for colorectal cancer treatment are fueling the growth of the colorectal cancer market in the region.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Middle East & Africa colorectal cancer market at a substantial CAGR during the forecast period.

Middle East & Africa Colorectal Cancer Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Colorectal Cancer Market Segmentation

The Middle East & Africa colorectal cancer market is segmented into modality, end user, and country. Based on modality, the Middle East & Africa colorectal cancer market is segmented into diagnosis type, therapy type, and imaging type. In 2022, the diagnosis type segment held the largest market share and is expected to register the highest CAGR during the forecast period. Based on end user, the Middle East & Africa colorectal cancer market is bifurcated into hospitals and diagnostic & research laboratories. In 2022, the hospitals segment held a larger market share. Based on country, the Middle East & Africa colorectal cancer market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia held the largest market share in 2022.

Abbott, Amgen Inc., Bruker Corporation, Clinical Genomics Technologies Pty Ltd., EDP Biotech Corporation, Epigenomics AG, F. Hoffmann-La Roche AG, Quest Diagnostics, and VolitionRx Limited are among the leading companies operating in the Middle East & Africa colorectal cancer market.

At 2.5% CAGR, the Middle East & Africa Colorectal Cancer Market is speculated to be worth US$ 1,076.92 Million by 2028, says The Insight Partners

According to The Insight Partners’ research, the Middle East & Africa colorectal cancer market was valued at US$ 885.81 million in 2022 and is expected to reach US$ 1,076.92 million by 2028, registering an annual growth rate of 2.5% from 2022 to 2028. Various benefits offered by generic drugs and growing pharmaceutical industry in emerging economies are the critical factors attributed to the market expansion.

Personalized medicine is a relatively new approach. However, it is rapidly expanding in the healthcare sector, where medical doctors can select a treatment based on a patient's genetic profile, which can minimize harmful side effects and lead to successful results in a short time.

Cancer personalized medicine involves studying individuals' genetic makeup for tumor growth. By studying patient’s genetic makeup, the oncologist can customize the treatment depending on the patient’s genetic mutations. For instance, two of the most common inherited colorectal cancer syndromes include familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC). However, determining the type of mutation in the cancer patient provides crucial information for the type of treatment that needs to be given to the patient.

Before personalized medicines, every patient received the same treatment for colorectal cancer. However, with the advent of personalized medicines, patients are now given treatments based on their genetic makeup. In such cases, the patient’s tissue is excised to carry out the genetic diagnosis process. The patient’s tissue sample is checked for gene mutations, and chemotherapy is carried out depending on the type of mutation. This allows the right treatment to be performed at the right time, which reduces the mortality rate. Biomarker testing analyzes the genetic makeup of a patient's tumor. Furthermore, test results provide patients and their medical teams with important information about the type of treatment that could work best for the patient, hence the term "precision medicine." In 2020, the Colorectal Cancer Alliance (Alliance) launched Personalized Biomarker Patient Education Campaign to empower patients and caregivers with information regarding precision treatment planning in colorectal cancer through biomarker testing, which can help improve the chances of survival.

Due to these advantages of tailoring the treatment based on individuals' genetic profiles, the personalized medicine approach is expected to create many opportunities for the MEA colorectal cancer market.

On the contrary, pricing pressure on drug manufacturers hurdles the growth of Middle East & Africa colorectal cancer market.

The Middle East & Africa colorectal cancer market, based on modality, has been segmented into diagnosis type, therapy type, and imaging type. The therapy type segment held the largest share of the market of 38.5% market share in 2022, amassing US$ 340.61 million. It is projected to garner US$ 418.16 million by 2028 to expand at 2.6% CAGR during 2022–2028.

By the end user, the Middle East & Africa colorectal cancer market is bifurcated into hospitals and diagnostic & research laboratories. With 52.9% share of the domain, the hospitals segment dominated the market in 2022. It accrued US$ 468.41 million in 2022 and is estimated to generate US$ 588.17 million by 2028 to grow at a CAGR of 2.9% over the forecast period.

Our regional analysis states that the Saudi Arabia captured 27.3% market share in 2022. It was assessed at US$ 241.16 million in 2022 and is likely to hit US$ 298.16 million by 2028, exhibiting a CAGR of 2.7% during the forecast period.

Key players dominating the Middle East & Africa colorectal cancer market are Abbott, Amgen Inc., Bruker Corporation, Clinical Genomics Technologies Pty Ltd., EDP Biotech Corporation, Epigenomics AG, F. Hoffmann-La Roche AG, Quest Diagnostics, and VolitionRx Limited among others.

Few latest developments among key market players are as follows:

In April 2022, Bruker announced the launch of innovative 7 Tesla and 9.4 Tesla conduction-cooled Maxwell magnets for its market-leading preclinical magnetic resonance imaging (MRI) systems portfolio. Following the success of its BioSpec Maxwell 3 Tesla model, the new range of Maxwell 7 Tesla and 9.4 Tesla magnets eliminates the need for liquid Helium or Nitrogen refills, while offering high-field sensitivity and resolution for advanced preclinical MRI and PET/MR research. In May 2022, Bruker launches a novel MALDI HiPLEX-IHC tissue imaging solution for timsTOF fleX using AmberGen's HiPLEX-IHC peptide code antibody probes in combination with unbiased lipidomics, glycomics and metabolomics tissue imaging. Improved product efficacy and new development will improve company's product portfolio. Contact Us

Contact Person: Sameer Joshi

Phone: +1- 646- 491- 9876

Email id: [email protected]

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study.

1.2 The Insight Partners Research Report Guidance.

1.3 Market Segmentation

1.3.1 MEA Colorectal Cancer Market – By Modality.

1.3.2 MEA Colorectal Cancer Market – By End User

1.3.3 MEA Colorectal Cancer Market – By Country

2. MEA Colorectal Cancer Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. MEA Colorectal Cancer– Market Landscape

4.1 Overview

4.2 MEA PEST Analysis

4.3 Expert Opinion

5. MEA Colorectal Cancer Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Increasing Prevalence of Colorectal Cancer

5.1.2 New Product Launches

5.1.3 Benefits Offered by Generic Drugs

5.2 Market Restraints

5.2.1 Pricing Pressure on Drug Manufacturers

5.3 Future Trends

5.3.1 Inclination Toward Personalized Medicine

5.4 Impact Analysis

6. MEA Colorectal Cancer Market– MEA Analysis

6.1 MEA Colorectal Cancer Market Revenue Forecast and Analysis

7. MEA Colorectal Cancer Market Analysis – By Modality

7.1 Overview

7.2 MEA Colorectal Cancer Market Revenue Share, By Modality 2022 & 2028 (%)

7.3 Diagnosis Type

7.3.1 Overview

7.3.2 Diagnosis Type: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.3.3 Immunohistochemistry

7.3.3.1 Overview

7.3.3.2 Immunohistochemistry: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.3.4 Stool Test

7.3.4.1 Overview

7.3.4.2 Stool Test: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.3.5 Flexible Sigmoidoscopy

7.3.5.1 Overview

7.3.5.2 Flexible Sigmoidoscopy: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.3.6 Colonoscopy

7.3.6.1 Overview

7.3.6.2 Colonoscopy: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.3.7 CEA Test

7.3.7.1 Overview

7.3.7.2 CEA Test: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.3.8 Other Test

7.3.8.1 Overview

7.3.8.2 Other Test: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4 Therapy Type

7.4.1 Overview

7.4.2 MEA Therapy Type: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.3 Chemotherapy

7.4.3.1 Overview

7.4.3.2 Chemotherapy: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.3.3 Alkylating Agent

7.4.3.3.1 Overview

7.4.3.3.2 Alkylating Agent: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.3.4 Antimetabolites

7.4.3.4.1 Antimetabolites: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.3.5 Others

7.4.3.5.1 Others: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.4 Immunotherapy

7.4.4.1 Overview

7.4.4.2 Immunotherapy: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.4.3 Panitumumab.

7.4.4.3.1 Overview

7.4.4.3.2 Panitumumab: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.4.4 Cetuximab.

7.4.4.4.1 Overview

7.4.4.4.2 Cetuximab: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.4.5 Bevacizumab

7.4.4.5.1 Overview

7.4.4.5.2 Bevacizumab: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.4.6 Others

7.4.4.6.1 Overview

7.4.4.6.2 Others: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.5 Chemoprotectant

7.4.5.1 Overview

7.4.5.2 Chemoprotectant: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.6 Others.

7.4.6.1 Overview

7.4.6.2 Others: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.5 Imaging Type

7.5.1 Overview

7.5.2 MEA Imaging Type: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.5.3 Computed Tomography (CT)

7.5.3.1 Overview

7.5.3.2 Computed Tomography (CT): Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.5.4 Magnetic Resonance Imaging (MRI)

7.5.4.1 Overview

7.5.4.2 Magnetic Resonance Imaging (MRI): Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.5.5 Others

7.5.5.1 Overview

7.5.5.2 Others: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

8. MEA Colorectal Cancer Market Revenue and Forecast To 2028 – By End User

8.1 Overview

8.2 MEA Colorectal Cancer Market Revenue Share, By End User 2022 & 2028 (%)

8.3 Hospitals

8.3.1 Overview

8.3.2 Hospitals: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Diagnostic and Research Laboratories.

8.4.1 Overview.

8.4.2 Diagnostic and Research Laboratories: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

9. MEA Colorectal Cancer Market Revenue and Forecast to 2028 – Country Analysis

9.1 Overview.

9.1.1 MEA Colorectal Cancer Market Revenue and Forecasts to 2028, By Country (%)

9.1.1.1 UAE Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)

9.1.1.1.1 UAE Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)

9.1.1.1.2 UAE: Colorectal Cancer Market – Revenue and Forecast to 2028, By Modality (US$ Million)

9.1.1.1.2.1 UAE: Colorectal Cancer Market, by Diagnosis Type – 2019–2028 (US$ Million)

9.1.1.1.2.2 UAE: Colorectal Cancer Market, by Therapy Type– 2019- 2028 (US$ Million)

9.1.1.1.2.2.1 UAE: Colorectal Cancer Market, by Chemotherapy– 2019- 2028 (US$ Million)

9.1.1.1.2.2.2 UAE: Colorectal Cancer Market, by Immunotherapy– 2019- 2028 (US$ Million)

9.1.1.1.2.3 UAE: Colorectal Cancer Market, by Imaging Type– 2019- 2028 (US$ Million)

9.1.1.1.3 UAE : Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)

9.1.1.2 Saudi Arabia Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)

9.1.1.2.1 Saudi Arabia Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)

9.1.1.2.2 Saudi Arabia: Colorectal Cancer Market – Revenue and Forecast to 2028, By Modality (US$ Million)

9.1.1.2.2.1 Saudi Arabia: Colorectal Cancer Market, by Diagnosis Type – 2019–2028 (US$ Million)

9.1.1.2.2.2 Saudi Arabia: Colorectal Cancer Market, by Therapy Type– 2019- 2028 (US$ Million)

9.1.1.2.2.2.1 Saudi Arabia: Colorectal Cancer Market, by Chemotherapy– 2019- 2028 (US$ Million)

9.1.1.2.2.2.2 Saudi Arabia: Colorectal Cancer Market, by Immunotherapy– 2019- 2028 (US$ Million)

9.1.1.2.2.3 Saudi Arabia: Colorectal Cancer Market, by Imaging Type– 2019- 2028 (US$ Million)

9.1.1.2.3 Saudi Arabia: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)

9.1.1.3 South Africa Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)

9.1.1.3.1 South Africa Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)

9.1.1.3.2 South Africa: Colorectal Cancer Market – Revenue and Forecast to 2028, By Modality (US$ Million)

9.1.1.3.2.1 South Africa: Colorectal Cancer Market, by Diagnosis Type – 2019–2028 (US$ Million)

9.1.1.3.2.2 South Africa: Colorectal Cancer Market, by Therapy Type– 2019- 2028 (US$ Million)

9.1.1.3.2.2.1 South Africa: Colorectal Cancer Market, by Chemotherapy– 2019- 2028 (US$ Million)

9.1.1.3.2.2.2 South Africa: Colorectal Cancer Market, by Immunotherapy– 2019- 2028 (US$ Million)

9.1.1.3.2.3 South Africa: Colorectal Cancer Market, by Imaging Type– 2019- 2028 (US$ Million)

9.1.1.3.3 South Africa: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)

9.1.1.4 Rest of MEA: Colorectal Cancer Market Revenue and Forecasts to 2028 (US$ Million)

9.1.1.4.1 Overview.

9.1.1.4.2 Rest of MEA: Colorectal Cancer Market Revenue and Forecasts to 2028 (US$ Million)

9.1.1.4.3 Rest of MEA: Colorectal Cancer Market – Revenue and Forecast to 2028, By Modality (US$ Million)

9.1.1.4.3.1 Rest of MEA:: Colorectal Cancer Market, by Diagnosis Type – 2019–2028 (US$ Million)

9.1.1.4.3.2 Rest of MEA: Colorectal Cancer Market, by Therapy Type– 2019- 2028 (US$ Million)

9.1.1.4.3.2.1 Rest of MEA: Colorectal Cancer Market, by Chemotherapy– 2019- 2028 (US$ Million)

9.1.1.4.3.2.2 Rest of MEA: Colorectal Cancer Market, by Immunotherapy– 2019- 2028 (US$ Million)

9.1.1.4.3.3 Rest of MEA: Colorectal Cancer Market, by Imaging Type– 2019- 2028 (US$ Million)

9.1.1.4.4 Rest of MEA: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)

10. Colorectal Cancer Market – Industry Landscape

10.1 Overview..

10.2 Growth Strategies In The Colorectal Cancer Market, 2022-2028.

10.3 Organic Developments.

10.3.1 Overview..

10.3.2 Organic Growth Strategies In The Colorectal Cancer Market, 2022-2028.

10.4 Inorganic Developments.

10.4.1 Overview..

10.4.2 Inorganic Growth Strategies In The Colorectal Cancer Market, 2022-2028.

11. Company Profiles

11.1 Epigenomics AG..

11.1.1 Key Facts.

11.1.2 Business Description.

11.1.3 Products and Services.

11.1.4 Financial Overview..

11.1.5 SWOT Analysis.

11.1.6 Key Developments.

11.2 Abbott

11.2.1 Key Facts.

11.2.2 Business Description.

11.2.3 Products and Services.

11.2.4 Financial Overview..

11.2.5 SWOT Analysis.

11.2.6 Key Developments

11.3 Amgen Inc.

11.3.1 Key Facts.

11.3.2 Business Description.

11.3.3 Products and Services.

11.3.4 Financial Overview..

11.3.5 SWOT Analysis.

11.3.6 Key Developments.

11.4 F. HOFFMANN-LA ROCHE LTD.

11.4.1 Key Facts.

11.4.2 Business Description.

11.4.3 Products and Services.

11.4.4 Financial Overview..

11.4.5 SWOT Analysis.

11.4.6 Key Developments.

11.5 Bruker Corporation.

11.5.1 Key Facts.

11.5.2 Business Description.

11.5.3 Products and Services.

11.5.4 Financial Overview..

11.5.5 SWOT Analysis.

11.5.6 Key Developments.

11.6 Quest Diagnostics Incorporated.

11.6.1 Key Facts.

11.6.2 Business Description.

11.6.3 Products and Services.

11.6.4 Financial Overview..

11.6.5 SWOT Analysis.

11.6.6 Key Developments.

11.7 Volitionrx Limited.

11.7.1 Key Facts.

11.7.2 Business Description.

11.7.3 Products and Services.

11.7.4 Financial Overview..

11.7.5 SWOT Analysis.

11.7.6 Key Developments.

12. Appendix

12.1 About The Insight Partners.

12.2 Glossary of Terms.

LIST OF TABLES.

Table 1.             UAE Colorectal Cancer Market, by Modality – Revenue and Forecast to 2028 (US$ Million)

Table 2.             UAE Colorectal Cancer Market, by Diagnosis Type – Revenue and Forecast to 2028 (US$ Million)

Table 3.             UAE Colorectal Cancer Market, by Therapy Type – Revenue and Forecast to 2028 (US$ Million)

Table 4.             UAE Colorectal Cancer Market, by Chemotherapy – Revenue and Forecast to 2028 (US$ Million)

Table 5.             UAE Colorectal Cancer Market, by Immunotherapy – Revenue and Forecast to 2028 (US$ Million)

Table 6.             UAE Colorectal Cancer Market, by Imaging Type – Revenue and Forecast to 2028 (US$ Million)

Table 7.             UAE: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)

Table 8.             Saudi Arabia Colorectal Cancer Market, by Modality – Revenue and Forecast to 2028 (US$ Million)

Table 9.             Saudi Arabia Colorectal Cancer Market, by Diagnosis Type – Revenue and Forecast to 2028 (US$ Million)

Table 10.          Saudi Arabia Colorectal Cancer Market, by Therapy Type – Revenue and Forecast to 2028 (US$ Million)

Table 11.          Saudi Arabia Colorectal Cancer Market, by Chemotherapy – Revenue and Forecast to 2028 (US$ Million)

Table 12.          Saudi Arabia Colorectal Cancer Market, by Immunotherapy – Revenue and Forecast to 2028 (US$ Million)

Table 13.          Saudi Arabia Colorectal Cancer Market, by Imaging Type – Revenue and Forecast to 2028 (US$ Million)

Table 14.          Saudi Arabia: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)

Table 15.          South Africa Colorectal Cancer Market, by Modality – Revenue and Forecast to 2028 (US$ Million)

Table 16.          South Africa Colorectal Cancer Market, by Diagnosis Type – Revenue and Forecast to 2028 (US$ Million)

Table 17.          South Africa Colorectal Cancer Market, by Therapy Type – Revenue and Forecast to 2028 (US$ Million)

Table 18.          South Africa Colorectal Cancer Market, by Chemotherapy – Revenue and Forecast to 2028 (US$ Million)

Table 19.          South Africa Colorectal Cancer Market, by Immunotherapy – Revenue and Forecast to 2028 (US$ Million)

Table 20.          South Africa Colorectal Cancer Market, by Imaging Type – Revenue and Forecast to 2028 (US$ Million)

Table 21.          South Africa: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)

Table 22.          Rest of MEA: Colorectal Cancer Market Revenue and Forecasts To 2028, By Modality (US$ Million)

Table 23.          Rest of MEA: Colorectal Cancer Market, by Diagnosis Type – Revenue and Forecast to 2028 (US$ Million)

Table 24.          Rest of MEA: Colorectal Cancer Market, by Therapy Type – Revenue and Forecast to 2028 (US$ Million)

Table 25.          Rest of MEA: Colorectal Cancer Market, by Chemotherapy – Revenue and Forecast to 2028 (US$ Million)

Table 26.          Rest of MEA: Colorectal Cancer Market, by Immunotherapy – Revenue and Forecast to 2028 (US$ Million)

Table 27.          Rest of MEA: Colorectal Cancer Market, by Imaging Type – Revenue and Forecast to 2028 (US$ Million)

Table 28.          Rest of MEA: Colorectal Cancer Market Revenue and Forecasts To 2028, By End User (US$ Million)

Table 29.          Recent Organic Growth Strategies In The Colorectal Cancer Market

Table 30.          Recent Inorganic Growth Strategies In The Colorectal Cancer Market

Table 31.          Glossary of Terms, MEA Colorectal Cancer Market

LIST OF FIGURES.

Figure 1.           MEA Colorectal Cancer Market Segmentation.

Figure 2.           MEA Colorectal Cancer Segmentation, By Country.

Figure 3.           MEA Colorectal Cancer Market Overview..

Figure 4.           Diagnosis Type Segment Held Largest Share Of Modality Segment In MEA Colorectal Cancer Market

Figure 5.           UAE is Expected To Show Remarkable Growth During The Forecast Period.

Figure 6.           MEA Colorectal Cancer Market – PEST Analysis.

Figure 7.           Comparison of Branded Drugs and Generic Drugs.

Figure 8.           MEA Colorectal Cancer Market Impact Analysis of Drivers And Restraints.

Figure 9.           MEA Colorectal Cancer Market – Revenue Forecasts And Analysis – 2020- 2028.

Figure 10.        MEA Colorectal Cancer Market Revenue Share, by Modality 2022 & 2028 (%)

Figure 11.        MEA Diagnosis Type: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 12.        MEA Immunohistochemistry: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 13.        MEA Stool Test: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 14.        MEA Flexible Sigmoidoscopy: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 15.        MEA Colonoscopy: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 16.        MEA CEA Test: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17.        MEA Other Test: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 18.        MEA Therapy Type: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 19.        MEA Chemotherapy: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 20.        Alkylating Agent: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21.        MEA Antimetabolites: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22.        MEA Others: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 23.        MEA Immunotherapy: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 24.        MEA Panitumumab: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25.        MEA Cetuximab: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26.        MEA Bevacizumab: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27.        MEA Others: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 28.        MEA Chemoprotectant: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29.        MEA Others: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 30.        MEA Imaging Type: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 31.        Computed Tomography (CT): Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 32.        MEA Magnetic Resonance Imaging (MRI): Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 33.        MEA Others: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 34.        MEA Colorectal Cancer Market Revenue Share, by End User 2022 & 2028 (%)

Figure 35.        MEA Hospitals: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 36.        MEA Diagnostic and Research Laboratories: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 37.        MEA: Colorectal Cancer Market Revenue Overview, By Key Country – Revenue (2022) (US$ Million)

Figure 38.        MEA Colorectal Cancer Market Revenue and Forecasts to 2028, By Country (%)

Figure 39.        UAE Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)

Figure 40.        Saudi Arabia Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)

Figure 41.        South Africa Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)

Figure 42.        Rest of MEA: Colorectal Cancer Market Revenue and Forecasts to 2028 (US$ Million)

Figure 43.        Growth Strategies In The Colorectal Cancer Market, 2022-2028.

The List of Companies - Middle East & Africa Colorectal Cancer Market

● Abbott

● Amgen Inc.

● Bruker Corporation

● Epigenomics AG

● F. Hoffmann-La Roche AG

● Quest Diagnostics  

● VolitionRx Limited

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Middle East & Africa colorectal cancer market

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa colorectal cancer market, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the colorectal cancer market, as well as those hindering it

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

TOP